Acute Coronary Syndromes: Initial Medical Therapy. ARC and NZRC Guideline 2011
2011; Wiley; Volume: 23; Issue: 3 Linguagem: Inglês
10.1111/j.1742-6723.2011.01422_19.x
ISSN1742-6731
Tópico(s)Sepsis Diagnosis and Treatment
ResumoEmergency Medicine AustralasiaVolume 23, Issue 3 p. 308-311 Acute Coronary Syndromes: Initial Medical Therapy. ARC and NZRC Guideline 2011 Australian Resuscitation Council, New Zealand Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation CouncilSearch for more papers by this author Australian Resuscitation Council, New Zealand Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation CouncilSearch for more papers by this author First published: 14 June 2011 https://doi.org/10.1111/j.1742-6723.2011.01422_19.xCitations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2010; CD007160. 2 Wilson AT, Channer KS. Hypoxaemia and supplemental oxygen therapy in the first 24 hours after myocardial infarction: the role of pulse oximetry. J R Coll Physicians Lond 1997; 31: 657–61. 3 Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. Br Med J 1976; 1: 1121–3. 4 Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005; 149: 1043–9. 5 Honderick T, Williams D, Seaberg D, Wears R. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med 2003; 21: 39–42. 6 McGettigan P, Henry D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. Jama 2006; 296: 1633–44. 7 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. 8 Funk D, Groat C, Verdile VP. Education of paramedics regarding aspirin use. Prehosp Emerg Care 2000; 4: 62–4. 9 Verheugt FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267–70. 10 Haynes BE, Pritting J. A rural emergency medical technician with selected advanced skills. Prehosp Emerg Care 1999; 3: 343–6. 11 Freimark D, Matetzky S, Leor J, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol 2002; 89: 381–5. 12 Barbash IM, Freimark D, Gottlieb S, et al. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. Cardiology 2002; 98: 141–7. 13 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349–60. 14 Quan D, LoVecchio F, Clark B, Gallagher JV, 3rd. Prehospital use of aspirin rarely is associated with adverse events. Prehosp Disaster Med 2004; 19: 362–5. 15 Dangas G, Mehran R, Guagliumi G, et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009; 54: 1438–46. 16 Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. The New England journal of medicine 363: 930–42. 17 Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31. 18 Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292: 45–54. 19 Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Jama 2007; 297: 591–602. 20 Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. The New England journal of medicine 2006; 355: 2203–16. 21 Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007; 298: 2497–506. 22 Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369: 907–19. 23 Wallentin L, Dellborg DM, Lindahl B, Nilsson T, Pehrsson K, Swahn E. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001; 24: I12–I4. 24 Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135–42. 25 Dubois CL, Belmans A, Granger CB, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003; 42: 1178–85. 26 Morrow DA, Antman EM, Murphy SA, et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial. Am Heart J 2007; 154: 1078–84, 1084.e1. 27 Thomas D, Giugliano RP. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. J Thromb Thrombolysis 2009; 27: 1–10. 28 Abhyankar AD, Pothiawala SE, Kazi GJ, Jha MJ, Petrolwala M. Use of enoxaparin in emergency room for improving outcomes of primary percutaneous coronary interventions for acute myocardial infarction. Indian Heart J 2008; 60: 39–44. 29 Welsh RC, Gordon P, Westerhout CM, Buller CE, O'Neill B, Armstrong PW. A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. Catheter Cardiovasc Interv 2007; 70: 341–8. 30 Zeymer U, Gitt A, Zahn R, et al. Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. EuroIntervention 2009; 4: 524–8. 31 Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. The New England journal of medicine 2008; 358: 2218–30. 32 Doll JA, Nikolsky E, Stone GW, et al. Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. J Interv Cardiol 2009; 22: 453–9. 33 Mehran R, Brodie B, Cox DA, et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute MyocardialInfarction (HORIZONS-AMI) Trial: study design and rationale. Am Heart J 2008; 156: 44–56. 34 Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374: 1149–59. 35 Parodi G, Antoniucci D, Nikolsky E, et al. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 3: 796–802. 36 Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. The New England journal of medicine 2009; 360: 1946–59. 37 Wang TY, White JA, Tricoci P, et al. Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial. Circulation 2011; 7. 38 Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. The New England journal of medicine 1985; 313: 1105–10. 39 Bertini G, Giglioli C, Rostagno C, et al. Early out-of-hospital lidocaine administration decreases the incidence of primary ventricular fibrillation in acute myocardial infarction. J Emerg Med 1993; 11: 667–72. 40 Dunn HM, McComb JM, Kinney CD, et al. Prophylactic lidocaine in the early phase of suspected myocardial infarction. Am Heart J 1985; 110: 353–62. 41 Wyman MG, Wyman RM, Cannom DS, Criley JM. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol 2004; 94: 545–51. 42 Paladino L, Sinert R, Brandler E. A review and meta-analysis of studies on the effect and timing of beta-blocker administration in patients with ST-segment elevation myocardial infarction. Hosp Pract (Minneap) 38: 63–8. 43 Al-Reesi A, Al-Zadjali N, Perry J, et al. Do beta-blockers reduce short-term mortality following acute myocardial infarction? A systematic review and meta-analysis. CJEM 2008; 10: 215–23. 44 Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622–32. 45 de Kam PJ, Voors AA, van den Berg MP, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol 2000; 36: 2047–53. 46 Voors AA, de Kam PJ, van den Berg MP, et al. Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk. Cardiovasc Drugs Ther 2005; 19: 119–24. 47 Wright RS, Bybee K, Miller WL, Laudon DA, Murphy JG, Jaffe AS. Reduced risks of death and CHF are associated with statin therapy administered acutely within the first 24 h of AMI. Int J Cardiol 2006; 108: 314–9. 48 Wright RS, Murphy JG, Bybee KA, Kopecky SL, LaBlanche JM. Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit. Mayo Clin Proc 2002; 77: 1085–92. 49 Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 1814–21. 50 Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588–636. Citing Literature Volume23, Issue3June 2011Pages 308-311 ReferencesRelatedInformation
Referência(s)